前列地尔联合丹参川芎嗪治疗高龄不稳定型心绞痛患者的临床观察 点击下载
| 论文标题： | 前列地尔联合丹参川芎嗪治疗高龄不稳定型心绞痛患者的临床观察 |
| 英文标题： | |
| 中文摘要： | 目的：观察前列地尔联合丹参川芎嗪治疗高龄不稳定型心绞痛患者的临床疗效及安全性。方法：选取2011年10月－2015年3月我院收治的不稳定性心绞痛患者150例，按照随机数字表法分为前列地尔组、丹参川芎嗪组、联合组，各50例。３组患者均给予常规治疗，前列地尔组在常规治疗基础上加用前列地尔注射液100 μg加入0.9％氯化钠注射液250 mL中，ivgtt，qd；丹参川芎嗪组在常规治疗基础上加用丹参川芎嗪注射液10 mL加入0.9％氯化钠注射液250 mL中，ivgtt，qd；联合组在常规治疗基础上给予等剂量前列地尔注射液和丹参川芎嗪注射液。观察两组患者治疗前后血液流变学指标（全血高切黏度、全血低切黏度、血浆黏度、红细胞比容、纤维蛋白原）、心功能指标[左心室射血分数（LVEF）、每搏输出量（SV）、左室舒张末期内径、舒张期室间隔厚度]、血清C反应蛋白（CRP）、一氧化氮（NO）、内皮素（ET）、超氧化物歧化酶（SOD）水平及临床疗效，并比较不良反应发生情况。结果：治疗前，两组患者血液流变学指标、心功能指标、CRP、NO、ET、SOD水平比较，差异均无统计学意义（P＞0.05）；治疗后，3组患者血浆黏度、全血高切和低切黏度、红细胞比容、纤维蛋白原、血清CRP、ET水平明显降低， LVEF、SV、血清NO、SOD水平明显升高，且联合组上述指标显著优于前列地尔组和丹参川芎嗪组，差异均有统计学意义（P＜0.05），前列地尔组和丹参川芎嗪组上述指标比较，差异均无统计学意义（P＞0.05）。联合组患者临床总有效率为90.00％，显著高于前列地尔组的74.00％和丹参川芎嗪组的72.00％，差异均有统计学意义（P＜0.05）。两组患者不良反应发生率比较，差异无统计学意义（P＞0.05）。结论：前列地尔联合丹参川芎嗪可有效降低不稳定型心绞痛患者的血液黏度，提高心功能，改善内皮功能，减轻心肌缺血缺氧损伤，同时疗效显著，且并未增加药物不良反应，安全性较高。 |
| 英文摘要： | OBJECTIVE： To observe clinical efficacy and safety of alprostadil combined with salvia ligustrazine in the treatment of aged patrents with unstable angina pectoris. METHODS： A total of 150 patients with unstable angina pectoris department of our hospital during Oct. 2011-Mar. 2015 were randomly divided into alprostadil group， salvia ligustrazine group and combination group according to random number table， with 50 cases in each group. Three groups received routine treatment. Alprostadil group additionally received Alprostadil injection 100 μg added into 0.9％ Sodium chloride injection 250 mL， ivgtt， qd， on the basis of routine treatment. Salvia ligustrazine group additionally received Salvia ligustrazine injection 10 mL added into 0.9％ Sodium chloride injection 250 mL， ivgtt， qd， on the basis of routine treatment. Combination group additionally received constant dose of Alprostadil injection and Salvia ligustrazine injection. Hemorheological indexes （high shear whole blood viscosity， low shear whole blood viscosity， plasma viscosity， hematocrit， fibrinogen）， cardiac function indexes （LVEF， SV， LVEFD， LVST）， serum CRP， NO， ET， SOD and clinical efficacies were observed in 2 groups before and after treatment； the occurrence of ADR was compared between 2 groups. RESULTS： Before treatment， there was no statistical significance in hemorheological indexes， cardiac function indexes or serum CRP， NO， ET， SOD level between 2 groups （P＞0.05）. After treatment， plasma viscosity， the whole blood high and low shear viscosity， hematocrit， fibrinogen， serum CRP and ET levels of 3 groups were decreased significantly， while LVEF， SV， serum levels of NO and SOD were increased significantly， combination group was significantly better than alprostadil group and salvia ligustrazine group， with statistical significance （P＜0.05）. There was no statistical significance in above indexes between alprostadil group and salvia ligustrazine group （P＜0.05）. Total response rate of combination group was 90.00％， which was significantly higher than 74.00％ of alprostadil group and 72.00％ of salvia ligustrazine group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Alprostadil combined with salvia ligustrazine can effectively reduce the blood viscosity of patients with unstable angina pectoris， improve cardiac function and endothelial function， reduce myocardial ischemia injury and show significant therapeutic efficacy and safety without increasing the incidence of ADR. |
| 期刊： | 2017年第28卷第26期 |
| 作者： | 赵仕玉，黄泽松，文娟，吉康 |
| 英文作者： | ZHAO Shiyu，HUANG Zesong，WEN Juan，JI Kang |
| 关键字： | 前列地尔；丹参川芎嗪；不稳定型心绞痛；疗效；安全性 |
| KEYWORDS： | Alprostadil； Salvia ligustrazine； Unstable angina pectoris； Therapeutic efficacy； Safety |
| 总下载数： | 81次 |
| 本日下载数： | 2次 |
| 本月下载数： | 81次 |
| 文件大小： | 619.60Kb |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！